Alzheimer’s Research Center

Alzheimer’s Research Center Offers Treatment Options, Picture a World without Memories

Alzheimer’s disease steals our memories and causes great anguish for patients and their families. Memories define us. Without them, who are we to ourselves and to our loved ones? The Alzheimer’s Research Corporation (ARC) founded in 1992 is committed to providing treatment alternatives for those individuals exhibiting signs of memory loss and possible/probable dementia.

For almost 20 years, ARC has conducted over 80 clinical trials mainly in the area of Alzheimer’s disease. ARC, an affiliate of Mid Atlantic Geriatric Association (MAGA) is located within the Manchester MAGA office. The practice location is unique in that it is part of a medical practice where medical, social and legal guidance is available in one location. Patients and caregivers have access to the healthcare team as needed.

Dr. Joshua Shua-Haim serves as the Principal Investigator for all clinical trials conducted. His expertise in the treatment of Alzheimer’s disease is without comparison. His research team consists of highly skilled professionals who collectively have over 50 years of research experience.

All trials are conducted with strict adherence to the Code of Federal Regulations and utilize Good Clinical Practices. The site has been audited by the Food & Drug Association (FDA) in 2000 and 2003. No contingencies were imposed as a result of these inspections. The site is recognized as star performers by many in the pharmaceutical industry.

If you or a loved one have been diagnosed with mild, moderate or advanced Alzheimer’s disease and are seeking new or adjuvant therapies, please visit the “Enrolling Studies” section to see what studies are currently enrolling at our site.

Research Team

  • Dr. Shua-Haim MD

    -- Clinical Professor of Medicine, UMDNJ-RWJ Medical School, New Brunswick, NJ
    -- Board certified Internal Medicine
    -- Board certified and fellowship trained in Geriatric Medicine
    -- 20 years experience as sub-investigator and principal investigator in Alzheimer’s disease clinical trials
    -- Vastly published in peer-reviewed journals
    -- Presenter at state, national and international Alzheimer’s disease Conferences
    -- President of Mid-Atlantic Geriatric Association

  • Vered Shua Haim RN, BSN

    -- President of the Alzheimer’s Research Corporation
    -- Functions as a rater and psychometrician
    -- 20 years experience in clinical research studies
    -- Served as a research coordinator for more than 50 double-blind AD studies for various pharmaceutical sponsors

  • Juanita Smitch

    VP Operations & Clinical Research Development
    Board Certified by ANCC as a Gerontological Nurse
    Senior Research Coordinator
    MAGA staff member 1995-2006, 2009 to present

  • Pamela Poole

    RN, Clinical Desk & Unblinded Research Pharmacist
    MAGA Staff Member since 2008

  • Patricia Brogan

    RN, APN
    ANCC Certified Clinical Nurse Specialist in Gerontology
    Practice Sites: Long Term Care; Assisted Living & Office
    MAGA staff member since 2009

Enrolling Studies

Sponsored by Accera

A 26 Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer’s Disease (AD) with an Optional 26 -Week Open-Label Extension

Sponsored by Lundbeck

Randomized, double-blind, parallel-group, placebo controlled, fixed dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with acetylcholinesterase inhibitor; Study 3

Please contact Juanita M Smith, Senior Research Coordinator at 732-657-6100 or fill out the form below with any questions regarding the above.